quality medical treatment.
The plasma of convalescent Covid-19 patients has been collected to set up an emergency plasma reserve, and convalescent plasma therapy has been applied in clinical treatment. As of May 31, convalescent plasma had been collected from 2,765 recovered patients, and 1,689 patients had been treated with the therapy, with positive results.
Early intervention for patients with mild symptoms. China has been quick to have patients with mild symptoms admitted to designated medical facilities for early medical intervention, and has done its best to prevent mild cases from worsening. The national clinical treatment network has been expanded to include more than 10,000 hospitals dedicated to the treatment of Covid-19 patients. A national network of medical treatment coordination has also been formed to provide technical support through online consultation.
In Wuhan, faced with surging infections and considering that 80 percent of cases were mild, the city government mobilized resources to repurpose stadiums and exhibition centers into 16 temporary treatment centers. With some 14,000 beds, these centers were able to admit all confirmed mild cases for treatment. This helped to reduce infections and virus transmission in communities and prevent mild cases from worsening. The 16 treatment centers received a total of more than 12,000 patients; 8,000 and more were cured and discharged; and more than 3,500 were transferred to hospitals. While in service, these facilities had zero cases of infection, death, or relapse.
Temporary treatment centers, or Fangcang shelter hospitals, are a major innovative solution that provided enough beds to admit all confirmed cases, thus turning the tide in the battle against Covid-19. An article in The Lancet wrote, "To relieve the huge pressure on the healthcare system, Fangcan shelter hospitals have also been crucial."[1]
Reviewing diagnostic and therapeutic plans and applying effective ones on a broad scale. China's diagnostic and therapeutic plans for Covid-19 have been developed and improved through clinical practice, medical research, experimentation and regular reviews. Based on scientific knowledge and accumulated evidence, R&D results and the diagnostic and therapeutic regimens that proved effective were incorporated in the national diagnosis and treatment plans. These include seven versions of the diagnosis and treatment protocol, three editions of the protocol for severe and critical cases, two editions of the manual for mild case management, two editions of convalescent plasma therapy treatment protocol, and one rehabilitation treatment program for patients discharged from hospitals. All these protocols and plans have contributed to
- ↑ The Lancet: "Sustaining Containment of COVID-19 in China", April 18, 2020. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30864-3/fulltext.
